Opus Genetics, Inc.
IRD · Nasdaq · United States
Share price · IRD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IRD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Sep 2026+32.0%
- 2 Sep 2026+16.2%
- 30 Jul 2026+10.7%
Nothing announced by IRD that day or the session before.
- 27 Jul 2026+8.8%
Nothing announced by IRD that day or the session before.
- 24 Jun 2026-9.1%
Nothing announced by IRD that day or the session before.
- 5 Jun 2026-13.1%
Nothing announced by IRD that day or the session before.
- 4 Jun 2026+10.5%
Nothing announced by IRD that day or the session before.
- 27 Feb 2026+15.9%
Nothing announced by IRD that day or the session before.
- 9 Feb 2026+12.3%
Nothing announced by IRD that day or the session before.
- 6 Feb 2026+16.7%
Nothing announced by IRD that day or the session before.
Share of unusual movement by asset
For each asset, the share of IRD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
OPGx-LCA5events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 23% |
| Sessions with no dated event | — | 76% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | LCA5 (lebercilin) gene replacementGene therapy / editing | Leber Congenital Amaurosis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.1M | $14M | $89M | $47M-$14M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.8M | $11M | $89M | $8.1M-$12M operating cash flow | report ↗ |
| 2026-Q1 | $2.2M | $11M | $60M | $66M-$13M operating cash flow | report ↗ |
| 2025-Q3 | $3.1M | $6.4M | $31M+ $0 short-term inv. | $17M-$6.2M operating cash flow | report ↗ |
| 2025-Q2 | $2.9M | $6.0M | $32M+ $0 short-term inv. | $7.4M-$10M operating cash flow | report ↗ |
| 2025-Q1 | $4.4M | $8.0M | $42M+ $0 short-term inv. | $8.2M-$9.0M operating cash flow | report ↗ |
| 2024-Q3 | $3.9M | $9.0M | $37M+ $0 short-term inv. | $7.5M-$5.1M operating cash flow | report ↗ |
| 2024-Q2 | $1.1M | $6.1M | $41M+ <$0.1M short-term inv. | $7.8M-$7.3M operating cash flow | report ↗ |
| 2024-Q1 | $1.7M | $4.8M | $47M+ <$0.1M short-term inv. | $7.1M-$5.7M operating cash flow | report ↗ |
| 2023-Q3 | $12M | $3.5M | $42M+ <$0.1M short-term inv. | —-$3.0M operating cash flow | report ↗ |
| 2023-Q2 | $3.7M | $4.7M | $40M+ <$0.1M short-term inv. | $5.0M$1.0M operating cash flow | report ↗ |
| 2023-Q1 | $1.8M | $5.6M | $39M+ <$0.1M short-term inv. | $5.8M-$3.6M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $2.8M | $14M+ $0.1M short-term inv. | $4.5M-$4.5M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $3.2M | $17M+ $0.1M short-term inv. | $4.9M-$3.8M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $4.8M | $19M+ $0.1M short-term inv. | $6.6M-$6.2M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $14M | $31M | $45M+ $0 short-term inv. | $12M-$35M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $11M | $27M | $30M+ $0 short-term inv. | $14M-$26M operating cash flow | report ↗ |
| 2023-FY | $19M | $18M | $51M+ <$0.1M short-term inv. | $2.5M-$1.1M operating cash flow | report ↗ |
| 2022-FY | $40M | $14M | $43M+ $0.1M short-term inv. | —$14M operating cash flow | report ↗ |
| 2021-FY | $0.6M | $15M | $25M+ $0.2M short-term inv. | $14M-$19M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($324K), 24 sales ($19.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-03 | Magrath George · director, Chief Executive Officer | Open-market sale | 28,258 | $3.90 | $110K | Form 4 |
| 2026-10-23 | Magrath George · director, Chief Executive Officer | Open-market sale | 9,591 | $3.58 | $34K | Form 4 |
| 2026-10-23 | Gagnon Robert E. · Chief Financial Officer | Open-market sale | 14,000 | $3.55 | $50K | Form 4 |
| 2026-10-23 | YERXA BENJAMIN R · director, President | Open-market sale | 7,669 | $3.55 | $27K | Form 4 |
| 2026-10-23 | SCHACHLE JOSEPH K · Chief Operating Officer | Open-market sale | 4,767 | $3.56 | $17K | Form 4 |
| 2026-10-23 | YERXA BENJAMIN R · director, President | Open-market sale | 25,520 | $3.53 | $90K | Form 4 |
| 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund; Foundation Fighting Blindness, Inc. · director; director | Open-market sale | 556,000 | $4.96 | $2.8M | Form 4 |
| 2026-09-09 | Magrath George · director, Chief Executive Officer | Option exercise | 392,157 | $1.15 | $451K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 79 reporting institutions held 45.4M shares ($203.4M, 47.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Caligan Partners LP | 6,075,028 | $27.6M |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6,029,775 | $27.4M |
| 3 | BIOS Capital Management, LP | 3,683,429 | $16.8M |
| 4 | Balyasny Asset Management L.P. | 2,718,029 | $12.4M |
| 5 | MILLENNIUM MANAGEMENT LLC | 2,630,432 | $12.0M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,449,987 | $11.1M |
| 7 | MARSHALL WACE, LLP | 2,313,380 | $10.5M |
| 8 | Boxer Capital Management, LLC | 2,250,000 | $10.2M |
| 9 | ADAR1 Capital Management, LLC | 1,849,004 | $8.4M |
| 10 | PERCEPTIVE ADVISORS LLC | 1,835,842 | $8.4M |
| 11 | Nantahala Capital Management, LLC | 1,681,330 | $7.7M |
| 12 | Woodline Partners LP | 1,354,030 | $6.2M |
| 13 | BOOTHBAY FUND MANAGEMENT, LLC | 1,189,113 | $5.4M |
| 14 | FARALLON CAPITAL MANAGEMENT LLC | 1,000,000 | $4.5M |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 823,383 | $3.7M |